ARS Pharmaceuticals, Inc. (SPRY)
4.23
-0.33
(-7.24%)
USD |
NASDAQ |
Oct 09, 16:00
4.24
+0.01
(+0.24%)
After-Hours: 20:00
ARS Pharmaceuticals Cash from Operations (Quarterly) : -60.93M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -60.93M |
| March 31, 2026 | -44.95M |
| December 31, 2025 | -43.48M |
| September 30, 2025 | -47.05M |
| June 30, 2025 | -39.59M |
| March 31, 2025 | -40.74M |
| December 31, 2024 | 42.00M |
| September 30, 2024 | -14.47M |
| June 30, 2024 | -7.279M |
| March 31, 2024 | -6.71M |
| December 31, 2023 | -17.40M |
| September 30, 2023 | -12.76M |
| June 30, 2023 | -16.67M |
| Date | Value |
|---|---|
| March 31, 2023 | -12.43M |
| December 31, 2022 | 11.40M |
| September 30, 2022 | -5.682M |
| June 30, 2022 | -6.974M |
| March 31, 2022 | -6.925M |
| December 31, 2021 | 27.89M |
| September 30, 2021 | -19.12M |
| June 30, 2021 | -14.14M |
| March 31, 2021 | -12.20M |
| December 31, 2020 | -11.10M |
| September 30, 2020 | -7.029M |
| June 30, 2020 | -5.443M |
| March 31, 2020 | -7.628M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Capricor Therapeutics, Inc. | -31.49M |
| Sionna Therapeutics, Inc. | -22.22M |
| Nektar Therapeutics | -75.77M |
| Ardelyx, Inc. | -6.399M |
| Kyntra Bio, Inc. | -3.991M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 41.57M |
| Cash from Financing (Quarterly) | 3.197M |
| Free Cash Flow | -196.60M |
| Free Cash Flow Per Share (Quarterly) | -0.6135 |
| Free Cash Flow to Equity (Quarterly) | -61.08M |
| Free Cash Flow to Firm (Quarterly) | -58.45M |
| Free Cash Flow Yield | -46.89% |